Evidence map›Paper›PMID 37166482›Full record

ArticleApplied microbiology and biotechnology2023

Four thermostatic steps: A novel CRISPR-Cas12-based system for the rapid at-home detection of respiratory pathogens.

Jianhua Fang, Jing Liu, Na Cheng, Xiuhua Kang, Zhanchao Huang, Guoyu Wang, Xiaofeng Xiong, Tian Lu, Zhenghua Gong, Zhigang Huang and 2 more

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jianhua Fang *Department of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Jing Liu *Department of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Na ChengDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Xiuhua KangDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Zhanchao HuangDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Guoyu WangDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Xiaofeng XiongDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China.
Tian LuJiangxi Zhongke Yanyuan Biotechnology Co, Ltd, Nanchang, Jiangxi, 341000, People's Republic of China.
Zhenghua GongJiangxi Zhongke Yanyuan Biotechnology Co, Ltd, Nanchang, Jiangxi, 341000, People's Republic of China.
Zhigang HuangEmergency Department, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Jun CheShenzhen Institute of Quality & Safety Inspection and Research, Shenzhen, 518036, China. 890513@qq.com.
Tianxin XiangDepartment of Infection Control in Jiangxi Province, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 341000, People's Republic of China. txxiangmed@163.com.ORCID http://orcid.org/0000-0002-1673-6077

Funding

the Science and Technology Plan of Health Commission in Jiangxi Province 202210018
6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) in 2019 has severely damaged the world's economy and public health and made people pay more attention to respiratory infectious diseases. However, traditional quantitative real-time polymerase chain reaction (qRT-PCR) nucleic acid detection kits require RNA extraction, reverse transcription, and amplification, as well as the support of large-scale equipment to enrich and purify nucleic acids and precise temperature control. Therefore, novel, fast, convenient, sensitive and specific detection methods are urgently being developed and moving to proof of concept test. In this study, we developed a new nucleic acid detection system, referred to as 4 Thermostatic steps (4TS), which innovatively allows all the detection processes to be completed in a constant temperature device, which performs extraction, amplification, cutting of targets, and detection within 40 min. The assay can specifically and sensitively detect five respiratory pathogens, namely SARS-CoV-2, Mycoplasma felis (MF), Chlamydia felis (CF), Feline calicivirus (FCV), and Feline herpes virus (FHV). In addition, a cost-effective and practical small-scale reaction device was designed and developed to maintain stable reaction conditions. The results of the detection of the five viruses show that the sensitivity of the system is greater than 94%, and specificity is 100%. The 4TS system does not require complex equipment, which makes it convenient and fast to operate, and allows immediate testing for suspected infectious agents at home or in small clinics. Therefore, the assay system has diagnostic value and significant potential for further reducing the cost of early screening of infectious diseases and expanding its application. KEY POINTS: • The 4TS system enables the accurate and specific detection of nucleic acid of pathogens at 37 °C in four simple steps, and the whole process only takes 40 min. •A simple alkali solution can be used to extract nucleic acid. • A small portable device simple to operate is developed for home diagnosis and detection of respiratory pathogens.

Indexed as

COVID-19AnimalsCatsCRISPR-Cas SystemsHumansNucleic Acid Amplification TechniquesReal-Time Polymerase Chain ReactionReverse TranscriptionSARS-CoV-2Sensitivity and SpecificityCRISPR-Cas12Point-of-Care TestingRespiratory pathogensSARS‑CoV‑2

Identifiers

PMID37166482
PMCPMC10173909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.